Biomarker ID | 17 |
PMID | 15067324 |
Year | 2004 |
Biomarker | MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2+CHAF1A+CDS2+IER3+PPFIA3+COPEB+FOS+JUNB+ZFP36 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Differentially Expressed in Recurrent Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Recurrence Vs No Recurrence |
Type of Biomarker | Prognostic |
Cohort | 21 patients were divided into two subgroups representing prostate cancer with recur- rent (8 patients) and nonrecurrent (13 patients). Validation set consisted of 79 patients with 37 recurrent and 42 non recurrent) |
Senstivity | Recurrent Cancer Prediction: 88% |
Specificity | Non Recurrent Cancer Prediction: 92% |
AUC | NA |
Accuracy | 90% |
Level Of Significance | p<0.0001 |
Method Used | RNeasy or Fast-Tract kits |
Clinical | No |
Remarks | Results shown for Training Set |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NIPA2, Wnt5, KIAA0476, ITPR1, TCF2, CHAF1A, CDS2, IER3, PPFIA3, KLF6, FOS, JUNB, ZFP36 |